Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non-Muscle-Invasive Bladder Cancer.
Ian M McElreeVignesh T PackiamRyan L SteinbergSarah L MottPaul T GellhausKenneth G NeppleMichael A O'DonnellPublished in: The Journal of urology (2022)
In a heavily pretreated population, our results suggest valrubicin and docetaxel is an effective rescue treatment for patients with recurrent non-muscle-invasive bladder cancer. Further prospective evaluation is needed.